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Abstract: This review will summarise the recent discoveries and current state of research on short
noncoding RNAs derived from tRNAs—known as tRNA-derived fragments (tRFs). It will describe
the features of the known subtypes of these RNAs; including sequence characteristics, protein
interactors, expression characteristics, biogenesis, and similarity to canonical miRNA pathways.
Also their role in regulating gene expression; including mediating translational suppression, will
be discussed. We also highlight their potential use as biomarkers, functions in gene regulation and
links to disease. Finally, this review will speculate as to the origin and rationale for the conservation
of this novel class of noncoding RNAs amongst both prokaryotes and eukaryotes.
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1. Introduction
The recent increase in rapid and inexpensive RNA sequencing has led to the discovery of a
myriad of novel noncoding RNA species. These studies have also shed light on the variations
in small RNA expression amongst different organisms, developmental stages and disease states
(reviewed in [1]). This has resulted in a rich catalogue of RNAs with biological functions that
includes well-established players such as endogenous siRNAs (endosiRNAs), microRNAs (miRNAs)
and PIWI-interacting RNAs (piRNAs).
There is mounting evidence that >85% of the human genome is readily transcribed [2], and it
has become clear that regulatory small RNAs can be processed from novel RNA sources (reviewed
in [3,4]). However, the functionality of small RNAs from abundant species of “housekeeping”
noncoding RNAs (e.g., rRNA, tRNA, snRNA, snoRNA, etc.) remains a highly studied topic. In this
review, we examine the current state of research on short RNAs derived from transfer RNA (tRNA);
called tRNA-derived fragments (tRFs).
2. Characteristics and Biogenesis of tRFs
Transfer RNAs are an extremely conserved and highly abundant RNA species with a
well-defined role in protein translation. The biogenesis of mature tRNAs (reviewed in [5] and shown
in Figure 1) results from the transcription of pre-tRNA and subsequent trimming of the 51 and 31
ends by the endonucleases RNase P and RNase Z, respectively. In addition, introns are present in a
small percentage of eukaryotic tRNAs and are spliced out by tRNA-specific enzymatic complexes [6].
Following extensive post-transcriptional modification and folding, mature tRNAs are exported to the
cytoplasm. A properly folded tRNA contains four distinct arms: the D arm, anticodon loop, TψC
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arm and variable loop (see Figure 1). A 31 CCA trinucleotide is also added at the acceptor stem by
a nucleotidyl transferase as it is not genomically encoded [7]; with the exception of certain bacterial
species, including Escherichia coli, that do encode it [8].
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Figure 1. tRNA biogenesis, types of tRFs, nucleases involved in their biogenesis, and examples of 
their functions. Outline of mature tRNA biogenesis (dark grey) from pol(III)-transcribed pre-tRNA 
precursors which undergo nuclease cleavage by RNase P and RNase Z, enzymatic modification 
including addition of CCA trinucleotide and folding into mature tRNA. Four recognised types of 
tRFs and their identified nucleases (if any) shown including (A) 5′ tRF; (B) 3′ CCA tRF; (C) 3′ U tRF; 
(D) itRF. Examples of functions for tRFs in the literature (light grey) including: (1) gene repression of 
mRNAs via 3′UTR targeting [9,10] and reporter construct silencing [11]; (2) targeting of ribosomes 
and inhibition of translation [12,13]; (3) modulators of cell proliferation [14]; (4) promotion of 
Xrn2-mediated exonuclease degradation of mRNAs [15]; (5) displacement of Ybx1 protein from 
mRNA and promotion of degradation [16]; (6) sense-induced trans-silencing [17]. 
2.1. tRNA-Halves versus tRNA-Derived Fragments (tRFs) 
tRNA-derived short RNAs can be broadly classified into two main groups; tRNA-halves and 
tRNA-derived fragments; likely depending on their biogenesis. Half-tRNAs are produced by 
ribonucleolytic cleavage of mature tRNAs under stress conditions by Angiogenin in higher 
eukaryotes [18,19] and by the RNase Rny1 in yeast [20]. In eukaryotes, these have been referred to as 
tRNA-derived stress-induced small RNAs (tiRNAs) [19] and correspond to a single cleavage of 
mature tRNA in the anticodon loop. However, there is ambiguity over whether some tRNA-derived 
short RNAs are classified as tRNA-halves or tRFs in many transcriptome studies. This is due to the 
absence of stress conditions which would typically favour the production of conventional 
half-tRNAs or tiRNAs. In contrast, transfer RNA-derived RNA fragments (tRFs) are a seemingly 
distinct group of small RNAs generated through the endonucleolytic cleavage of both mature and 
precursor tRNAs, usually near the D- or TψC-arm [20,21]. In this review, we mainly consider these 
tRFs that are not derived from a sole cleavage site in the anticodon loop and are shorter than 32 nt. 
Also considered will be long (>35 nt) tRFs that do not involve canonical anticodon cleavage. A 
summary of tRFs identified in the literature is shown in Table 1.  
Figure 1. tRNA biogenesis, types of tRFs, nucleases involved in their biogenesis, and examples of
their functions. Outline of mature tRNA biogenesis (dark grey) from pol(III)-transcribed pre-tRNA
precursors which undergo nuclease cleavage by RNase P and RNase Z, enzymatic modification
including addition of CCA trinucleotide and folding into mature tRNA. Four recognised types of
tRFs and their identified nucleases (if any) shown including (A) 51 tRF; (B) 31 CCA tRF; (C) 31 U
tRF; (D) itRF. Examples of functions for tRFs in the literature (light grey) including: (1) gene
repressio of mRNAs via 31UTR targeting [9,10] and eport r construct silencing [11]; (2) targeting of
ribosomes and inhibition of translation [12,13]; (3) modulators of cell proliferation [ 4]; (4) promotion
of Xrn2-mediated exonuclease degradation of mRNAs [15]; (5) displacement of Ybx1 protein from
mRNA and promotion of degradation [16]; (6) sense-induced trans-silencing [17].
2.1. tRNA-Halves versu tRNA-Derived Fragments (tRFs)
tRNA-derived short RNAs can be broadly classified into two main groups; tRNA-halves
and tRNA-derived fragments; likely depending on their biogenesis. Half-tRNAs are produced
by ribonucleolytic cleavage of mature tRNAs under stress conditions by Angiogenin in higher
eukaryotes [18,19] and by the RNase Rny1 in yeast [20]. In eukaryotes, these have been referred
to a tRNA-deriv d stress-induced sm ll RNAs (tiRNAs) [19] and correspond to a single cleavage of
mature tRNA in he anticodon loop. Ho ever, there is ambig ity over whether s me tRNA-derived
short RNAs are classified as tRNA-halves or t Fs in many transcriptome studies. This is due to the
absence of stress conditions which would typically favour the production of conventional half-tRNAs
or tiRNAs. In contrast, transfer RNA-derived RNA fragments (tRFs) are a seemingly distinct group
of small RNAs generated through the endonucleolytic cleavage of both mature and precursor tRNAs,
usually near the D- or TψC-arm [20,21]. In this review, we mainly consider these tRFs that are not
derived from a sole cleavage site in the anticodon loop and are shorter than 32 nt. Also considered
will be long (>35 nt) tRFs that do not involve canonical anticodon cleavage. A summary of tRFs
identified in the literature is shown in Table 1.
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Table 1. Types of tRFs identified in the literature.
Group Organism/ Cell Type/Cell Line Length (nt) Type(s) Nuclease-Identified Co-Factor(s) Ref.
Plant
Phosphate-starved A. thaliana roots 19 51 [22]
Rice (Oryza sativa) embryogenic callus N.S 51 and 31 [23]
Brassica rapa 27–30, 15–18, 23 51 [24]
Arabidopsis thaliana 19 51 and 31 CCA Ago1,2,4,7 [25]
Barley (Hordeum vulgare L) Normal and
phosphate-starved conditions N.S N.S [26]
Archaea
Haloferax volcanii 40 31 U [27]
Haloferax volcanii 26 51 Small ribosomal subunit [12]
Fungi Magnaporthe oryzae ~35 Mainly 5
1 [28]
Phytophthora infestans 25–30 (peaks at 27 and 30) 51 Dcl1-independent; Ago1 and 4 dependent [29]
Flatworm Schistosoma japonicum eggs 19–25 51 [30]
Protozoa
Tetrahymena ~23 31 CCA Twi12 [31]
Tetrahymena 18–22 31 CCA Twi12 [15]
Giardia lamblia 18–32 51 and 31 [32]
Trypanosoma cruzi N.S N.S [33]
Exosomes from Leishmania donovani,
Leishmania braziliensis 38–46 5
1 and 31 CCA [34]
Yeast Schizosaccharomyces pombe 23 51 Dicer-independent [35]
Insect
Drosophila (multiple species) 23–29 51 and 31 CCA Ago1 and Ago2 [36]
Bombyx mori 51: 33 and 1831 CCA:40 and 21 51 and 31 CCA BmAgo2 [37]
Mammal
KSHV-infected primary-effusion lymphoma cell
line; MEFs 5
1: 14–15 31 CCA: 17–18 51 and 3 CCA' Dicer/DGCR8-independent 31 CCA/Ago2 in MEF [38]
5-8F (nasopharyngeal carcinoma) 19 31 U [39]
Mature human B-cells 22 3‘ CCA Dicer Ago1–4 [10]
HEK293 (kidney) and HCT116 (colon carcinoma) 20–22 31 CCA, 31 U Dicer (31 CCA) RNase Z (31U) Ago3/4 > Ago1/2 [11]
Mouse embryonic stem cells 21 31U Dicer [40]
HIV-1 infected MT4 cells 18 31 CCA Dicer Ago2 [17]
LNCaP and C4-2 (prostate carcinoma) 18–22 51, 31 CCA and 31 U Rnase Z for 31U [14]
HeLa (cervical carcinoma) 19 51 Dicer Ago1/2 (poorly) [41]
HepG2 (liver carcinoma) 22 31 CCA [42]
HeLa (cervical carcinoma) 19–21 51 Polysomes [13]
MDAMB231 (human breast carcinoma) 27–29 51 Piwi-l4 [43]
Healthy and cancerous human tissue 19–30 5’, 3’and itRF [44]
Human breast cancer cell lines 59–87 All Ybx1 [16]
Human testis and testicular germ cell tumour 25–36 51 [45]
Exosomes from human semen 18–19, 30–34 51 [46]
Exosomes from human dendritic cells and T-cells 30, 40–50 31 CCA [47]
CLP1-mutant mouse embryonic fibroblasts
(MEFs) 41–46 5
1 intronic [48]
Extracellular vesicles from MCF7/MCF10A
(breast cancer) 18 3
1 [49]
Multiple Bacteria, yeast, nematode, fly, mouse and humantissues and cancer cell lines 5
1: 15,22,32, 31 CCA: 18–22 51, 31 CCA and 31 U Dicer/DGCR8-independent in mice, fly andS.pombe Ago1, 3, 4 (5
1 and 31 only) [50]
tRF: transfer RNA-derived fragments. N.S: Not specified.
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2.2. Types of tRFs and Nomenclature
Studies reporting on the different types of tRFs are yet to retain a consistent nomenclature to
describe them. In this review, we maintain the nomenclature we proposed previously [51]. Here, we
classify four main types of tRF based on their position of origin in pre-tRNA or mature tRNA (see
Figure 1). The 51 tRFs are generated from a cleavage in the TψC-arm of mature tRNA extending to
the 51 end of the molecule. The 31 tRFs are a second class of tRFs that originate from a cleavage in
the D-arm and includes the trinucleotide CCA post-transcriptional modification. A third class of tRF
is sourced from the 31 end of a pre-tRNA molecule—known as 31 U tRFs. Here, cleavage is typically
performed by RNase Z and results in the presence of characteristic poly-U residues at the 31 terminus.
Another more recently characterised tRF are those derived from a combination of cleavages in the
anticodon loop and either D-arm or TψC-arm, collectively termed internal tRFs (itRFs) [44].
2.3. Biogenesis of tRFs
The production of small RNAs from tRNA precursors is an emerging field of investigation.
Aside from the production of half-tRNAs via the cleavage of mature tRNAs under stress conditions,
little is known about the biogenesis of shorter (<32 nt) tRNA fragments. In some cases, tRFs appear
to be produced in a manner similar to the canonical miRNA pathway. Therefore, focus has been
put on identifying if components of the miRNA processing pathway (Dicer, Drosha, Dgcr8 etc.)
are required for tRF biogenesis. Until recently, tRF production appeared to be Dicer-dependent in
mammals [11,17,40,41], however subsequent analyses have shown that both 51 and 31 tRFs can be
produced independently of Dicer and Dgcr8 in HEK293 cells [38]. Recent work has confirmed that
the canonical miRNA machinery is dispensable for the production of tRFs in Phytophthora infestans,
Drosophila, mice and Schizosaccharomyces pombe [29,35,50].
Mature tRNA biogenesis normally requires the endonuclease RNase Z to trim the 31 trailer from
pre-tRNA. In mammalian cells, this enzyme has been shown to be required for 31U tRF generation in
cultured human cells [11,14]. Another tRNA endonuclease, Elac2/RNaseZL, has been demonstrated
to be required for generation of a 31U tRF named tRF-1001 in human colon cancer cells [14].
Angiogenin is also capable of producing short 31 tRFs in in vitro cleavage assays by cleaving in the
TψC arm [38]. Other types of tRNA-fragments can be produced by Angiogenin under non-stress
conditions [20,52,53], and in mouse embryonic fibroblasts deficient in the tRNA kinase Clp1 [48].
The reason for hypervariability in mechanism of tRF generation is yet to be fully understood,
particular whether it is a result of multiple mechanisms or other cell-specific factors that dictate the
types of tRF produced. In addition, tRFs may be generated by the aberrant recognition and cleavage
of misfolded tRNAs. The correct modification of tRNA lowers conformation flexibility and increases
thermal stability (reviewed in [54]). A loss of this stability and associated increases in flexibility may
cause tRNAs to become the substrate for various endonucleases. Nevertheless, is appears that tRFs
can be produced independently of well-known endonucleases such as Dicer, leaving the possibility
for yet unknown mechanisms to contribute to their production.
2.4. Proteins Associated with tRFs
Due to the increase in reporting on tRFs, much attention has been brought to identifying the
proteins and pathways they interact with. Many studies have since identified binding partners
which may provide clues to their possible functions. As many tRFs share similar features to RNAs
in the siRNA and miRNA pathways, many groups have focused on identifying which (if any) of
the Argonaute proteins associate with tRFs. Couvillion and colleagues were first to identify that
Twi12, a Piwi/Ago protein homolog, is a binding partner of a 23 nt tRF in the ciliate protozoa
Tetrahymena thermophila [15,31].
The first description of Argonaute/tRF interactions in more complex eukaryotes was reported
by Haussecker et al. Here, both 31 U and 31 CCA tRFs displayed a preference for binding Ago3/4
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over Ago1/2 in HEK293 cells [11]. Subsequent analyses have identified that both 51 and 31CCA
tRFs bind Ago2 in mouse embryonic fibroblasts (MEFs) [38] and the human T-cell leukemia cell line
(MT4) [17], respectively. Other analyses have shown that 51 tRFs poorly associate with Argonaute
proteins Ago1 and Ago2 [41] in the human cancer line HeLa. This finding has been largely verified
in bioinformatics analyses of PAR-CLIP data from Ago1–4 immunoprecipitations from HEK293 cells,
where both 51 tRFs and 31 CCA tRFs display binding affinity for Ago1,3 and 4 but not Ago2 [50].
51 tRFs have also been demonstrated to bind the human Piwi protein Hiwi2 in a breast cancer cell
line [43]. Interestingly, tRFs also appear to be differentially loaded onto Ago proteins depending on
minor differences in cell subtype [44]. Studies in less complex organisms support the notion that tRFs
associate with Argonaute proteins in plants [25], silkworm [37] and fly [36].
The association of tRFs with the translational machinery has also been investigated. Two studies
have shown that both 19 and 26 nt 51 tRFs associate with polysomes in HeLa cells [13] and in the
halophile Haloferax volcanii [12], respectively. Importantly, both these studies demonstrated that
protein synthesis is down-regulated as a result of this binding.
2.5. Subcellular Localisation
A great deal of information about the function and biogenesis of small noncoding RNAs stems
from the subcellular localization of their precursor and mature components. For example, the miRNA
pathway comprises pri-miRNAs and Drosha-processed pre-miRNA precursors in the nucleus and
Dicer-processed and Ago-loaded mature miRNAs in the cytoplasm. In contrast, the subcellular
compartmentalisation of tRF precursors and biogenesis is much less understood. Limited evidence
suggests that the vast majority of mature 51 and 31 CCA mammalian tRFs are cytoplasmic [11,39],
with large proportions of the nuclear-processed 31 U tRFs are also exported to the cytoplasm. Lee and
colleagues have also shown that 31 U tRFs can be processed by the endonuclease Elac2 after export to
the cytoplasm [14]. In contrast, Kumar and colleagues demonstrated that 51 tRFs are more abundant
in the nucleus of human HeLa cells [50]. Further analysis of diversity in the location and processing of
tRFs may be indicative of separate functions within the cells. If tRFs are involved in gene regulation,
the prevalence of cytosolic fragments is suggestive of translational and/or RNA control, rather than
transcriptional or epigenetic regulation. In addition to the localisation of tRFs inside cells, numerous
studies have reported on tRFs being expressed in extracellular vesicles and exosomes secreted from
mammalian and protozoan cells. Here, 51 and 31 CCA tRFs have been identified in exosomes secreted
from human semen [46] and human dendritic cells and T-cells [47], respectively. In addition, the
intracellular parasites Leishmani donovanii and Leishmania braziliensis release exosomes containing long
51 and 31 CCA tRFs [34].
2.6. tRNA-Derived Fragments Are Deeply Conserved in Nature
A common theme that has been identified by deep sequencing surveys of small ncRNAs is the
universality of tRFs in almost every branch of life. To date, tRFs of any of the three subtypes have
been documented in bacteria [50], algae [29], archaea [12,27], protozoa [15,31,32,34], flatworms [30],
plants [22–26], yeast [35,50] and mammals [11,13,14,16,17,23,38–45,50]. Also, the online database
tRFdb reveals 552, 559, 433, 320 and 649 tRF sequences from human, mouse, Drosophila, S.pombe
and C. elegans, respectively [55]. This is perhaps not surprising considering the universality of
precursor tRNA throughout all taxonomic groups. However, tRFs are expressed in less complex
organisms, such as bacteria and archaea, which do not possess the canonical miRNA or siRNA
pathway. Numerous studies have shown that tRFs can be produced in the absence of many of these
conventional ribonucleases, and therefore may be indicative of an underlying more ancient regulatory
system that is not dependent on canonical gene silencing pathways. Importantly, even though
prokaryotes lack much of the typical miRNA processing machinery, they do however universally
express several isotype-specific tRNA endonucleases [56,57].
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The conservation of these and other related endonucleases in eukaryotes suggests that tRF
biogenesis may be a fundamental pathway overshadowed by more recently evolved and perhaps
more specific regulatory pathways. A complicating aspect of this is the deep conservation of
tRNA-half generation under oxidative and/or nutritional stress [19,58–60]. Distinguishing these
two prevalent types of tRNA-derived small RNAs will be crucial to elucidate if they have mutually
exclusive or shared functions. Studying tRFs poses an interesting experimental challenge both
bioinformatically and biochemically, owing to the abundance of their precursor transcripts and
frequency of contamination in NGS data. Strategies that overcome these problems center on correctly
identifying the origin of tRFs, and are an emerging bioinformatic discipline [61,62].
3. Functionality and Significance of tRFs
Despite mounting evidence for the generation of tRFs in almost all cell types, a recurring concern
is that tRFs are aberrant degradation products of endonuclease activity. A common response to this
is typically three-fold. Firstly, numerous groups have demonstrated that the processing of mature
tRNA into tRFs is remarkably site-specific, generating tRFs with highly defined lengths amongst
different cell types. Secondly, tRF expression does not correlate with the abundance of their respective
precursor tRNAs [22,41,43,44]; with the exemption of those identified in Tetrahymena [31]. The
generation of tRFs appears to be restricted to specific isotypes of tRNAs, in some cases dictating which
endonuclease is involved. This suggests that tRNA isotype selection and processing is non-random.
Finally, tRFs exhibit features of functional regulatory molecules, some of which are shown in Figure 1.
3.1. miRNA-Like Regulation of Gene Expression
Until recently, a major deficiency in our understanding of tRF biology was that there was little
known about the function of tRFs once they were generated. Perhaps the most powerful function tRFs
could have would be the ability to behave like miRNAs and siRNAs and repress the expression of
endogenous targets. Indeed, several studies have demonstrated the ability of both 51 tRFs and 31 CCA
tRFs to target the 31UTR of specific mRNAs and repress their translation. The first exhibition of this
was a 22-nt long 31 CCA tRF that uses canonical miRNA machinery to repress replication protein
A1 (RPA1) mRNA, among other genes [10]. More recently, Deng and colleagues demonstrated that
the 31 portion of a 5’ tRF (named tRF5-GluCTC) targets the 31UTR of APOER2. Remarkably it was
shown that tRF5-GluCTC is overexpressed in response to respiratory syncytial virus (RSV) infection
and promotes further infection by modulating the level of Apoer2 [9]. These reports are in addition
to the numerous instances of annotated miRNAs with silencing capacity that are derived from tRNAs
which is discussed in the next section.
Prior to this, similar forms of luciferase reporter construct silencing have been observed in the
human cancer cells HEK293 and HCT116. Here, the inhibition of a 31 CCA tRF (cand14) with an
antisense oligonucleotide resulted in derepression of the reporter construct by ~30%–40%. In the
same study, a 31 U tRF (cand45) alone did not appear to repress its target. However unexpectedly, the
addition of an antisense strand to cand45 resulted in a dramatic silencing of the luciferase target by
~80%. This mechanism was coined sense-induced trans-silencing (SITS) [11]. Some studies propose
that tRFs may serve to bind complementary RNAs and form duplexes that the canonical miRNA
machinery can recognise and cleave [17].
3.2. The tRF/miRNA Mixup
A consequence of the advent of advanced bioinformatic methodologies has been a rapid influx
of novel noncoding small RNAs. Recent findings have suggested that there is misannotation and
cross-mapping between miRNA precursors and other types of ncRNAs (e.g., tRNA, rRNA etc.). This
phenomenon was identified in silico in 2010 and 2011 by identifying eight tRFs incorrectly annotated
as miRNAs (miR-tRFs) [63,64]. Those specifically identified were hsa-miR-1280, hsa-miR-720,
hsa-miR-1308 and hsa-miR-886-5p [63], plus hsa-miR-4284 and hsa-miR-3182 [64]. Both studies
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identified hsa-miR-1274a and hsa-miR-1274b [63,64]. Most of these have since been removed from
miRBase, but interestingly, hsa-miR-4284 and hsa-miR-3182 remain at the time of preparing this
manuscript. These two miRNAs have been independently identified in Ago2 immunoprecipitates
from either human stem cells (hsa-miR-4284) [65] or melanoma (hsa-miR-3182) [66].
More recent studies have shown that many of these miR-tRFs exhibit differential expression
in human tissues and cancer. It has been demonstrated that the oncoprotein YB-1 interacts with
a suite of noncanonical small RNAs in breast cancer, including two miR-tRFs; miR-4284 and
miR-1308 [63,64,67]. Human skin has also been shown to express two ~22 nt tRFs derived from
tRNAIle(TAT) and tRNAPseudo(TTA) [68], the former of which is a homolog of a mouse miRNA
(mmu-miR-1983). A miR-tRF derived from tRNALeu (annotated as hsa-miR-1280) has also shown
to be elevated in human breast cancer tissue [69]. Enrichment of the miR-tRFs miR-720 (tRNAThr)
and miR-1274b (tRNALys) have also been observed in serum-deprived extracellular vesicles (EVs)
secreted from human breast cancer cells [49].
Finally, one study has identified a 22 nt tRF named CU1276, which is derived from the 51 end of
the tRNAGly(GCC) and is down-regulated in lymphoma and primary cancers. This tRF associates with
Ago proteins, is dependent on Dicer for biogenesis, and represses endogenous genes (e.g., RPA1) by
targeting 31 gUTRs [10]. This is a chief example of a tRF behaving like a miRNA but not being derived
from a canonical pri-miRNA gene.
3.3. Regulating Translational Efficiency
Aside from a role for tRFs in mediating miRNA/siRNA-like silencing, several studies suggest a
role for tRFs in global translational repression. In the archeabacteria Haloferax volcanii, Gebetsberger
and colleagues showed that a 26-nt 51 tRF (tRNAVal) directly binds the small ribosomal subunit and
reduces translation by inhibiting peptidyl transferase activity. [12]. In human cells, a 19-nt 51 tRF
derived from glutamyl tRNA (Gln19) was able to repress a luciferase assay target irrespective of
the presence of canonical miRNA-like target sites in HeLa cells. Further work showed that the
mechanism is likely targeting translational elongation [13]. An interesting motif identified in human
tRFs is a GG-dinucleotide at base-positions 17–18 in 51 tRFs derived from tRNAGln, tRNAGlu and
tRNAVal [13]. Artificial tRFs containing this GG-dinucleotide motif but other random sequences
maintained their function in translational repression.
3.4. tRFs Roles in the Regulation of Cell Viability, RNA Degradation and RNA Stability
Other putative roles for tRFs that have been identified include the regulation of proliferation and
cell viability and modulating the turnover of different RNAs. Lee and colleagues have previously
showed that (tRF-1001) is essential for cell proliferation, and results in G2 accumulation and reduced
viability in HCT116 cells [14]. Interesting, this tRF-1001 is identical to cand45, previously reported by
Haussecker and colleagues [11]. Another tRF that shows proliferative inhibition is the 51 tRF named
(CU1276). Here, proliferation is hypothesized to be suppressed via the downstream loss of Rpa1
functionality [10].
RNA stability is another key mediator of gene regulation, determining the rates at which RNA
molecules are degraded by exonucleases; ultimately changing protein levels. Two reports have
demonstrated that 31 CCA tRFs can modulate at least two different RNA turnover mechanisms.
In Tetrahymena, 31 CCA tRFs have been shown to stimulate the activity of the nuclear 51 to 31
exonuclease Xrn2 [15]. In breast cancer cells, a subset of 31 CCA tRFs contain putative binding
sites for the RNA-binding protein Ybx1, which is known to stabilise oncogenic transcripts. Here,
tRFs competitively bind Ybx1 and displace mRNA transcripts; reducing their stability and promoting
degradation [16].
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3.5. tRFs Association with Diseases; Potential Biomarkers
Half-tRNAs have a relatively well described role in disease and infection [9,33,61,70–75]. The
first hints that tRFs are important in disease states was described in 2009. Here, an 18-nt long
31 tRF was found to be dramatically upregulated in response to HIV infection in the human T-cell
line MT4 [17]. Also, the human pathogen Giardia lambia induces expression of several tRFs during
infection and differentiation, suggestive of possible modulation of host genes [32].
The available literature signifies that tRFs are predominately expressed in highly proliferative
human cancer cells [11,13,14,16,17,38,39,41–45,50]. This could simply be a product of the popularity
and power of human cancer cells as model organisms. However, many studies report an
association between tRF expression and higher rates of proliferation [13,14]. 31 CCA tRFs have been
demonstrated to repress proliferation and the DNA damage response in B-cell lymphoma cells [10].
A short 10–16 nt tRF (of unknown type) has also been shown to repress growth in human urinary
bladder carcinoma [76]. The overwhelming evidence suggests that the expression of tRFs and cell
proliferation are deeply entwined; possibly suggestive of a use in medicine for the manipulation of
highly proliferative cells such as cancer cells.
The heterogeneity and stability of some small RNAs makes them useful as biomarkers for
diseases such as cancer. Telonis and colleagues have reported that the transcriptional abundance
of different tRFs can distinguish normal breast tissue from triple negative (ER-/PR-/HER2-) and
triple positive breast cancer ER+/PR+/HER2+ [44]. In other breast cancer studies, tRFs have been
shown to regulate tumour-suppressive genes and are associated with less tumorigenic breast cancer
cell types [16]. Finally, Rounge and colleagues identified three 51 tRFs that are differentially expressed
in testicular germ cell tumours (TGCTs) [45].
4. Rationale for Evolution of tRFs
Despite much research into cataloging the expression of tRFs, little progress has been made on
identifying if they are bona fide regulators of genes or by-products of improper tRNA processing.
This section aims to discuss possibilities for the expansion of this novel noncoding RNA.
4.1. tRFs: The Forgotten Gene Regulation Mechanism
tRFs are expressed in all of the three domains of life; eukarya, archea and bacteria. Bacteria do
not express the canonical small RNA pathway (e.g., Dicer, miRNA, etc.), however they do appear
to have their own rudimentary gene regulatory system that uses small RNAs (for review see [77]).
The cleavage of tRNAs by nucleases into various small RNAs has also been observed in bacterial
species [77,78]. It should be noted however that as yet, these tRFs have not been shown to exhibit gene
regulatory functions. Nevertheless, we may therefore speculate that more complex organisms have
retained such an ancient pathway. Furthermore, as tRF expression appears to be linked to diseases
such as cancer, it may be that the tRF pathway is reactivated only upon the loss of RNA homeostasis
in unhealthy cells. Interestingly, the expression level of highly defined tRF species seems to rival and
in some cases exceeds that of miRNAs, especially in cancers [10,14,41]. Whether or not this increased
expression correlates with additional function remains to be investigated. A possibility we propose
is that tRFs are part of an ancient regulatory pathway that has been co-opted for use by more recently
evolved counterparts.
4.2. tRFs: Function Following Fortune
tRF expression appears to be intricately linked with proliferation, especially in cancer cells. This
may be because uncontrolled transcription leads to inadequate modification of mature tRNAs which
hinders their ability to properly fold. The formation of hairpin structures could lead to recognition by
endogenous nucleases such as Dicer and production of short RNAs [40]. This phenomena has already
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been observed for half-tRNAs [70]. The generation of tRFs may simply be a product of rampant
transcription in cancer cells that drives the recognition of tRNAs by endonucleases.
A hallmark of some cancers is the disruption of the normal miRNA pathway (for review see [79]).
Recent studies have reveal that Dicer is essential for the normal loading of miRNAs onto Ago2
protein and formation of competent RISC complexes [80]. Here, the loss of Dicer results in the
formation of RISC complexes loaded with small RNAs from unconventional sources. As tRFs have
been shown to associate with Ago proteins in virtually all animals, the possibility remains that the
disruption of the miRNA pathway in cancer leads to the accumulation of tRFs bound to Ago protein;
promoting their stability. However, the presence of tRFs in non-cancerous less complex organisms,
and inconsistent reports for the requirement for Dicer-mediated biogenesis, suggests this pathway is
not solely responsible for tRF generation. Interestingly, one report has demonstrated that whilst Ago2
binds tRFs in cancer cells, they cannot repress gene targets [81]. This poses the interesting possibility
that tRFs may function by binding and sequestering free Ago proteins and preventing them from
targeting mRNAs for silencing. This may help to explain why tRFs have been observed to have
non-specific effects on translational efficiency.
4.3. miRNA Sources Extend beyond pri-miRNA Genes
It has become increasingly clear that miRNAs are not always generated from hairpin pri-miRNA
structures, and that many other sources are likely to be possible [82]. As previously mentioned,
numerous miRNAs previously annotated on miRBase have been demonstrated to be derived from
tRNAs. Interestingly, most are now regarded as not “true” miRNAs. Much of tRNA biogenesis occurs
in the nucleus prior to cytoplasmic export, meaning the primary endonuclease enzymes responsible
for miRNA biogenesis (Dicer and Drosha) may also generate miRNAs from mature tRNAs as part of
normal gene silencing pathways. Is it plausible that tRFs evolved in parallel with miRNAs in higher
eukaryotes and represent an alternative source of RNA as guides for gene regulation? The lack of
mechanistic and functional data for most tRFs leaves this question open. Short RNAs have also been
shown to be produced from a wide variety of other ncRNA species including snoRNAs, ribosomal
RNAs, vault RNAs, etc [83]. It is therefore possible that tRFs represent a subset of noncanonical short
RNAs that are similarly processed and have gained regulatory roles in conjunction with miRNAs.
5. Concluding Remarks
Perhaps the most pertinent question is whether there is a defined function or established
evolutionary pathway for tRFs. Research to date is still in the phase of identifying such RNAs and
their functional studies are limited so far. Although some isolated functions have been indicated, the
vast majority of tRFs appear to operate via unknown mechanisms. Identifying if these pathways are
conserved between different species could unravel the biology of this new class of noncoding RNAs.
Also, describing mechanistically how tRFs regulate translation would assist our understanding of
their biology. This may resolve the hypothesis that tRFs act by binding and abrogating the miRNA
pathway. Nevertheless, our current understanding of tRFs suggests they are not merely byproducts of
random cleavage of tRNAs, yet remain as possible mediators of translational and/or gene regulation.
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